Francis Medical Receives Investment From JJDC

Francis Medical, a Maple Grove, Minnesota-based medical technology company developing minimally invasive treatments for urological cancers, has received an investment from Johnson & Johnson Innovation – JJDC, Inc. (JJDC). The investment amount was not disclosed.

The company will use the funding to expand its commercial operations, improve market access, strengthen physician training programmes, and support its planned Premarket Approval (PMA) submission to the US Food and Drug Administration (FDA) for treating clinically localized prostate cancer.

What is Francis Medical?

Francis Medical develops minimally invasive treatments for urological cancers. It's main product, the Vanquish System, is designed to treat prostate cancer using targeted thermal energy.

Read More:BluWave-ai Secures $8.1M in Series A-2 Funding

The system uses ultrasound and electromagnetic guidance to deliver water vapour energy to selected prostate tissue. This process aims to destroy cancerous tissue while limiting damage to nearby structures associated with urinary, and sexual function.

The Vanquish System received FDA 510(k) clearance in November 2025. The clearance was supported by interim results from the company's ongoing VAPOR 2 clinical study.

How Much Funding Has Francis Medical Raised?

Francis Medical has received an investment from Johnson & Johnson Innovation – JJDC. However, the company has not disclosed the investment amount or its total funding raised.

Who Invested in Francis Medical?

The investment came from Johnson & Johnson Innovation – JJDC, Inc., the investment arm of Johnson & Johnson Innovation.

The announcement did not disclose any other participating investors or the financial terms of the deal.

Why the Investment Matters

Francis Medical plans to use the capital to strengthen its commercial infrastructure, and expand access to the Vanquish System.

The funding will also support physician training and education programmes to help drive adoption of the technology. Another key priority is the companys planned PMA submission to the FDA for the treatment of clinically localized prostate cancer.

The investment is expected to provide financial support through this regulatory milestone.

Who founded Francis Medical?

Francis Medical was founded in 2018 by Michael Hoey and is headquartered in Maple Grove, Minnesota.

The company focuses on developing minimally invasive therapies for urological cancers, with an emphasis on treating cancerous tissue while limiting the impact on patients' surrounding healthy structures.

"This is a pivotal moment in Francis Medicals evolution as we prepare to transition from a limited commercial launch to a broader U.S. market presence," said Mike Kujak, President and CEO of Francis Medical. "With the support of JJDC, we are positioned to accelerate the development of our commercial organization, expand physician access to our technology and establish the infrastructure necessary to support sustainable growth.

Market and Business Growth

Francis Medical is advancing the Vanquish System through its VAPOR 2 pivotal clinical study. The trial is enrolling 235 patients with intermediate risk, localized prostate cancer across 26 clinical sites in the United States.

Initial results from the first 110 patients were published in The Journal of Urology. The findings showed that 91% of patients had no clinically significant MRI-visible cancer in the treated area after one procedure. No device related serious adverse events were reported.

The study also found that 93% of patients were satisfied or extremely satisfied with the procedure while 94% said they believed receiving the treatment was a wise decision.

What Happens Next?

Francis Medical plans to expand its commercial operations, improve market access, and strengthen physician education around the Vanquish System.

The company will also continue the VAPOR 2 study and prepare its planned FDA Premarket Approval submission for the management of clinically localized prostate cancer.

Read More:Alma Mater Footwear Receives Investment From BrknPar